Big data and computational biology strategy for personalized prognosis
Metrics: HTML 802 views | ?
Ghim Siong Ow1, Zhiqun Tang1, Vladimir A. Kuznetsov1,2
1Bioinformatics Institute, Singapore 138671
2School of Computer Engineering, Nanyang Technological University, Singapore 639798
Vladimir A. Kuznetsov, email: firstname.lastname@example.org
Keywords: personalized prognosis, risk stratification, ovarian cancer, aging, big data
Received: July 28, 2015 Accepted: May 01, 2016 Published: May 24, 2016
The era of big data and precision medicine has led to accumulation of massive datasets of gene expression data and clinical information of patients. For a new patient, we propose that identification of a highly similar reference patient from an existing patient database via similarity matching of both clinical and expression data could be useful for predicting the prognostic risk or therapeutic efficacy.
Here, we propose a novel methodology to predict disease/treatment outcome via analysis of the similarity between any pair of patients who are each characterized by a certain set of pre-defined biological variables (biomarkers or clinical features) represented initially as a prognostic binary variable vector (PBVV) and subsequently transformed to a prognostic signature vector (PSV). Our analyses revealed that Euclidean distance rather correlation distance measure was effective in defining an unbiased similarity measure calculated between two PSVs.
We implemented our methods to high-grade serous ovarian cancer (HGSC) based on a 36-mRNA predictor that was previously shown to stratify patients into 3 distinct prognostic subgroups. We studied and revealed that patient’s age, when converted into binary variable, was positively correlated with the overall risk of succumbing to the disease. When applied to an independent testing dataset, the inclusion of age into the molecular predictor provided more robust personalized prognosis of overall survival correlated with the therapeutic response of HGSC and provided benefit for treatment targeting of the tumors in HGSC patients.
Finally, our method can be generalized and implemented in many other diseases to accurately predict personalized patients’ outcomes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.